Search results
Showing 526 to 540 of 563 results for oral care
Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.
Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)
Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.
View recommendations for TA380Show all sections
Technology appraisal and highly specialised technologies appeals
Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
First HIV prevention injection for people unable to have daily PrEP recommended
A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small group of adults and young people unable to have daily pre-exposure prophylaxis (PrEP) tablets.
Agenda and papers of the NICE public board meeting on 19 March 2025
Agenda and papers of the NICE public board meeting on 22 March 2023
Agenda and papers of the NICE public board meeting on 20 March 2024
In the Labonte model, health behaviours are actions individuals take that affect their health positively or negatively such as smoking, substance abuse or physical activity.
Home Implementing NICE guidance Social care...
Agenda and papers of the NICE public board meeting on 25 September 2024
Agenda and papers of the NICE public board meeting on 22 September
Agenda and papers of the NICE public board meeting on 20 May 2025
Agenda and papers of the NICE public board meeting on 19 July 2023
Agenda and papers of the NICE public board meeting on 16 December 2022